Visium Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Visium Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-52,700	Closed	-$1.76M	–	339
2016 Q1	$1.47M	Sell	52,700 -814,417	-94%	-$17.8M	0.03%	413
2015 Q4	$30.9M	Buy	867,117 +5,697	+0.7%	+$201K	0.46%	41
2015 Q3	$28.5M	Buy	861,420 +25,098	+3%	+$1.04M	0.39%	50
2015 Q2	$35M	Buy	+836,322	New	+$32.4M	0.5%	36
2014 Q2	–	Sell	-227,936	Closed	-$5.55M	–	1088
2014 Q1	$5.55M	Sell	227,936 -878,686	-79%	-$22.2M	0.09%	215
2013 Q4	$27.7M	Sell	1,106,622 -140,587	-11%	-$3.32M	0.54%	38
2013 Q3	$34.3M	Sell	1,247,209 -780,578	-38%	-$16.3M	0.78%	26
2013 Q2	$36.8M	Buy	+2,027,787	New	+$27.9M	0.86%	25

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Visium Asset Management's ACAD Position: Q2 2016 in Review

Visium Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2016, closing a stake of 52,700 shares — an estimated $1.76M sold.

Visium Asset Management first reported a position in ACAD in Q2 2013 and held it in 8 quarters. The position peaked at $36.8M in Q2 2013. 228 funds tracked by Wall St. Rank hold ACAD as of Q2 2016.

Visium Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 52,700 Acadia Pharmaceuticals shares in Q2 2016, an estimated $1.76M.
Visium Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Visium Asset Management's Acadia Pharmaceuticals position peaked at $36.8M in Q2 2013.
228 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.